212 results about "Purine" patented technology

The invention provides a perovskite solar cell, a preparation method thereof and a photovoltaic module. The perovskite solar cell comprises a first electrode, a hole transport layer, a perovskite layer, an electron transport layer and a second electrode which are stacked in sequence. The material of the hole transport layer comprises a biomolecular material which is fixed on a self-assembly monomolecular layer material through an intermolecular force, and the biomolecular material comprises one or more of guanine, adenine, thymine, uracil, cytosine, hydroxymethylcytosine, xanthine, hypoxanthine, 6-mercaptopurine and corrin. According to the perovskite cell provided by the invention, the biomolecular material with a plurality of nitrogen heterocyclic structures and amino groups is added to generate multipoint hydrogen-bond interaction and pi-pi accumulation with the tail end of the SAM, so that the orderliness of molecular arrangement is improved, and the dipole direction and strength of the whole interface are regulated and controlled; and a coordination bond or hydrogen bond network is formed by the coordination compound and uncoordinated cations or anions in perovskite, so that interface defects are effectively passivated, and the thermal stability and the humid and hot life of a device are enhanced.

The present invention provides a method for producing ribose-1-phosphate that is simple and yields improved efficiency. [Solution] A method for producing ribose-1-phosphate, comprising a contact step to produce ribose-1-phosphate and hypoxanthine by contacting inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium in a reaction solution containing inosine, a phosphate donor, an enzyme having purine nucleoside phosphorylase activity, and a medium, wherein in the contact step, the hypoxanthine is present in an amount exceeding the saturation concentration relative to the medium.

The invention provides deuterium-enriched piperidinyl-methyl-purine amines and related compounds, pharmaceutical compositions, their use for inhibiting NSD2, and their use in the treatment of a disease or condition, such as cancer.

The invention provides application of a roxburgh rose extract in preparation of a product for treating hyperuricemia and regulation and control of a purine metabolic pathway, and belongs to the technical field of biological medicines. The roxburgh rose aqueous extract extracted from roxburgh rose pomace can effectively intervene in hyperuricemia through a dual action mechanism: on one hand, the roxburgh rose aqueous extract significantly inhibits the expression of xanthine oxidase (XOD) in the liver, and reduces the generation of uric acid; on the other hand, expression of key urate transporters (including GLUT9, URAT1, ABCG2 and OAT1) is regulated and controlled, uric acid is promoted to be excreted through the kidney, and therefore the blood uric acid level is reduced in a synergistic mode, a solid theoretical basis and technical support are provided for developing a new HUA prevention and treatment strategy based on natural products, and a new thought is provided for prevention and treatment of hyperuricemia.

The invention discloses a construction and verification method of an HEK293T cell line capable of stably overexpressing human ANT2, which comprises the following steps: cloning a human ANT2 gene, constructing the human ANT2 gene into a lentivirus expression plasmid pLVX-TRE3G, co-transfecting the lentivirus expression plasmid pLVX-TRE3G and a helper plasmid pLVX-Tet3G into an HEK293T-ACE2 cell, and carrying out puromycin and G418 pressurized screening and Western blot identification to obtain the HEK293T cell line capable of stably overexpressing human ANT2. A result shows that the expression quantity of the ANT2 is the highest when the HEK293T-ACE2-ANT2 cell is induced for 12 hours at the Doxycycline of 6mg / L; when the ANT2 is induced to express, the virus nucleic acid load and the N protein expression level after SARS-CoV-2 infection are obviously reduced, which indicates that the ANT2 has an inhibition effect on SARS-CoV-2 infection replication, and a cell model and an experimental basis are provided for exploring the effect of the ANT2 in virus infection resistance.

Novel and known substituted purine compounds and salts thereof act as adenosine A2a receptor (A2aR) antagonists for cancer immunotherapy, depression, anxiety, multiple sclerosis, NASH, scleroderma, ADHD, Alzheimer's and Parkinsons. Pharmaceutical compositions comprising such compounds, and methods of their use in treating depression are also taught.

This invention provides deuterium-enriched piperidinyl methylpurine amine salts, crystalline forms, pharmaceutical compositions, their use in inhibiting NSD2, and their use in treating diseases or ailments, such as cancer.

The invention discloses a method for improving the biomass and flavone content of a saussurea involucrata cell culture, which comprises the following steps of: culturing yellow-white saussurea involucrata callus on a culture medium at the temperature of 24 DEG C, illuminating for 16 hours / day, subculturing once every 15 days and subculturing for three times to obtain yellow-white or yellow-green callus which grows vigorously and is compact in structure; the preparation method of the culture medium comprises the following steps: weighing MS, cane sugar, naphthylacetic acid, 6-benzyladenine, coconut extract and agar in a container, adding distilled water, fully stirring, fixing the volume to 1 L, uniformly stirring, and adjusting the pH value to obtain a basic culture solution; carrying out high-pressure sterilization on the basic culture solution, pouring a flat plate, and cooling to obtain a culture medium; wherein the coconut extract is one or two of coconut water or coconut milk. By adding coconut water or coconut milk, the biomass of the saussurea involucrata callus can be remarkably increased in cooperation with the MS culture medium, and compared with an existing report, the increasing multiple is 2-3 times that of the existing report.

The invention belongs to the technical field of protein beverage processing and utilization, and particularly relates to soybean milk powder based on a white kidney bean extract and a preparation method of the soybean milk powder. The soybean milk powder is prepared by taking soybeans as a main raw material, the soybeans are subjected to peeling treatment, mechanical impurities, dust and soybean germs in the soybeans as well as purine, alkali and other components which are contained in peels and are harmful to a human body are removed, the content of bacteria is reduced, and the flavor of the soybean milk powder is optimized; the white kidney bean extract is added, and the white kidney bean extract contains an alpha-amylase inhibitor which can inhibit the activity of alpha-amylase, so that absorption of carbohydrates is delayed and partially blocked, the blood sugar level is favorably controlled, rapid increase of postprandial blood sugar is reduced, and the anti-saccharification effect is indirectly achieved; meanwhile, the white kidney bean extract is rich in high-quality protein, various amino acids, mineral substances, vitamins B1 and B2 and the like, so that the health level of a human body can be further improved.

To provide a beer-flavored beverage having an excellent taste and little astringency, while having a reduced content of purines. [Solution] A beer-flavored beverage having a purine content of 15 ppm or less and a peptide content of 35 to 50 kDa molecular weight of 1.5 to 50 ppm.

The invention discloses an NLRP3 inhibitor as well as a preparation method and application thereof. Specifically, the invention relates to a compound shown as a formula (NLRP3i-3) or a pharmaceutically acceptable salt thereof, the formula (I) is COCCNc1nc2c (c (= O) n (C) c (= O) n2C) n1Cc1cc (OC) ccc1N, and the chemical name is 8-((4-amino-2-methoxybenzyl)-7, 9-dimethyl-7, 9-dihydro-8H-purine-6, 8-diketone. The invention also provides a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound in preparation of drugs for preventing and / or treating NLRP3-mediated diseases. The disease is preferably myocardial ischemia reperfusion injury. Experimental results show that the compound provided by the invention has excellent NLRP3 inhibitory activity (IC50lt, 100nM), and has high selectivity to NLRP3 inflammasomes; good pharmacokinetic characteristics are achieved in a rat body, and the bioavailability is high; in myocardial ischemia reperfusion injury models of mice and rats, the composition can significantly reduce myocardial infarction area, reduce myocardial enzyme level, alleviate inflammatory response and improve heart function; preliminary toxicological evaluation shows that the safety is good. Therefore, the compound disclosed by the invention is expected to be developed into a novel medicine for treating NLRP3 related diseases such as myocardial ischemia-reperfusion injury.

The invention discloses a method for reducing the purine content of phaseolus calcaratus powder, and belongs to the technical field of edible bean processing. The method comprises the processes of acid-assisted hydrothermal treatment and isoelectric precipitation. The acid-assisted hydrothermal process comprises the following steps: mixing 0.1-1 mol / L of hydrochloric acid, 0.5-1 mol / L of phosphoric acid or 0.8-1 mol / L of citric acid with the phaseolus calcaratus powder, and stirring and heating at 60-70 DEG C; and the isoelectric precipitation is to precipitate and recover the phaseolus calcaratus protein under the condition that the pH value of the mixed system is 3-5. And freeze-drying the precipitate, and grinding to obtain the low-purine phaseolus calcaratus powder. The processing conditions can effectively reduce the purine content in the phaseolus calcaratus, so that the processing loss can be effectively controlled, and the higher protein content can be kept; the problem that the purine content in phaseolus calcaratus is high at present can be solved, and a new method is provided for research and development of low-purine phaseolus calcaratus products.

The present disclosure relates to filters configured for a spectroscopic antibiotic susceptibility analysis and a method for filtering a sample for a spectroscopic antibiotic susceptibility analysis. In one example, a method comprises providing a solution comprising bacteria incubated in a media to a well, filtering the solution via adsorption to trap at least a portion of the bacteria in a filter separate from the media. providing a solution of SERS active nanoparticles to the well, and spectroscopically analyzing the filter to determine the presence and / or absence of at least one of a purine and a pyrimidine. Methods of providing an internal standard in a spectroscopic antibiotic susceptibility test are also provided.

Methods of treating, reducing the risk of, preventing, or alleviating a symptom of inflammation or inflammatory gastrointestinal disease by administration of a modified bacterium providing purines, in particular hypoxanthine, to the mucosa of the intestine, and compositions containing modified bacteria useful in such methods.

This invention is in the field of medicinal chemistry. In particular, the invention relates to a new class of small-molecules having a 6,5-heterocyclic structure (e.g., compounds having a imidazo-pyridine structure, or compounds having a pyridinyl-purine structure) which function as inhibitors of DYRK1A, DYRK1B, and Clk-1, and are useful as therapeutics for the treatment of Alzheimer's disease, Down syndrome, diabetes (e.g., any type or form of diabetes, including type-1 or type-2), autoimmune diseases, inflammatory disorders (e.g., airway inflammation), cancer (e.g., glioblastoma, prostate cancer), diabetes, and other diseases.

The purpose of the present invention is to provide a novel beer-taste fermented alcoholic beverage in which, despite the purine concentration being reduced, deterioration of flavor and aroma, reduction in crispness of bitterness, and intensity of astringency resulting from the reduction in purine concentration are ameliorated. The present invention provides a beer-taste fermented alcoholic beverage having a purine concentration of 35,000 ppb or lower, wherein the iron concentration is 0.02 ppm or greater, and the furfuryl acetate concentration is 3 ppb or greater. According to the present invention, it is possible to provide a beer-taste fermented alcoholic beverage in which the purine concentration is reduced, wherein, despite the purine concentration being reduced, the flavor and aroma are excellent, and crispness of bitterness and intensity of astringency are improved, due to the iron concentration being set to a prescribed value.

This application discloses a purino[1,2-a]carbazolin derivative, its preparation method, and its application. Specifically, it discloses a compound having the structure shown in Formula I, or its stereoisomers, solvates, metabolites, pharmaceutically acceptable salts, cocrystals, or prodrugs: ; wherein R1 and R2 are each independently selected from hydrogen, hydroxyl, carboxyl, substituted or unsubstituted C1-C6 alkyl, -CONH-R3, and -COO-R4; wherein R3 is a substituted or unsubstituted C1-C5 alkyl, and the substituent can be any of cyano, halogen, alkylC1-C5 alkoxy, C1-C5 alkylsulfonyl, di(C1-C5 alkyl)amino, nitrogen-containing heterocyclic, aryl, and C1-C5 heteroaryl; R4 is selected from any of substituted or unsubstituted aryl C1-C5 alkyl and nitrogen-containing saturated heterocyclic C1-C5 alkyl. This compound can be used as a TDP1 inhibitor for antitumor therapy.

The present application provides: a phosphoribosylaminoimidazole-succinoylcarboxamide synthase variant; a microorganism comprising the variant; a composition for producing a purine nucleotide, the composition comprising the microorganism; and a method of producing a purine nucleotide, the method comprising the step of culturing the microorganism.

Provided herein is a eukaryotic cell expressing an exogenously introduced inosine 5'-monophosphate dehydrogenase (IMPDH) that is resistant to a purine biosynthesis inhibitor, uses thereof for producing therapeutic agents and treating a disease or disorder, as well as pharmaceutical compositions and methods of making thereof.

The present application relates to the field of molecular markers and animal genetic breeding technology, and particularly relates to a SNP marker affecting pig purine base content and application thereof. Based on three test pig populations of American purebred Landrace, American purebred Large White and American purebred Duroc, the present application uses pig whole genome resequencing and GWAS analysis to research and determine 15 SNP markers significantly affecting pig purine base content. By selecting the advantageous alleles of the above SNP markers, the frequency of the advantageous alleles can be increased generation by generation, the corresponding purine content can be reduced or increased, the progress of pig genetic improvement can be accelerated, and the economic benefits of pig breeding can be effectively improved.

Therapeutic agents such as Prasugrel, a thienopyridine ADP receptor inhibitor, which inhibit ADP mediated signaling through the P2Y12 receptor, done or in combination with an angiotensin II receptor blocker (ARB) such as Losartan that specifically blocks the angiotensin II type 1 (AT1) receptors, have been shown to be effective in reducing thrombosis and stenosis of grafts, including vascular grafts and tissue engineered vascular grafts ("TEVGs") in multiple in vivo, and that the combination of a inhibitor of the purinergic receptors P2Y12 such as Prasugrel, with losartan, an angiotensin II type 1 receptor inhibitor, more than additively reduced the incidence of TEVG stenosis. In a preferred embodiment, a multi-dosing unit for treatment to reduce stenosis delivers a 2-week course of losartan and Prasugrel.

The application of CpG oligonucleotides in drugs for diabetic cardiac autonomic neuropathy: Experiments have confirmed that CpG oligonucleotide 1826 can reduce the activation of satellite glial cells in the stellate ganglion and the expression of inflammatory cytokines, inhibit the expression of purine 2Y12 receptors, and reduce lipid peroxidation damage to alleviate ferroptosis in stellate ganglion neurons, thereby improving cardiac autonomic nerve function. Examples of CpG oligonucleotide 1826 demonstrate that CPG-ODN with anti-inflammatory effects or with anti-damage protective effects on the sympathetic nervous system has preventive and therapeutic effects in diabetic cardiac autonomic neuropathy and sympathetic nerve injury-related diseases.

The present application relates to the field of food processing technology, and provides a method and a device for purine reduction, and an equipment and an electronic equipment and a storage medium. The method for purine reduction includes the following steps: first cooling step: performing first cooling treatment on a food material to be treated at a first preset cooling rate to reduce a temperature of the food material to be treated to a temperature below a freezing point. By performing first cooling treatment on a food material to be treated at a first preset cooling rate to reduce a temperature of the food material to be treated to a temperature below a freezing point, the activity of ATP-degrading enzyme in the food material to be treated can be rapidly inhibited, which can quickly and effectively inhibit the generation of hypoxanthine, thereby reducing the generation of hypoxanthine, reducing the risk of hyperuricemia and gout, and having little effect on the taste and quality of the food material.

The invention discloses application of a PAPSS2 inhibitor in preparation of a medicine for treating bladder cancer. Based on the principle that PAPSS2 inhibits p53 expression through sulfurylation modification and mediates purine metabolism reprogramming to promote bladder cancer progress, a sulfurylation rate-limiting enzyme PAPSS2 is used as a core target spot for bladder cancer treatment, the target spot is a key upstream molecule for regulating purine metabolism reprogramming, and high expression of the target spot is directly related to poor prognosis of bladder cancer; the PAPSS2 inhibitor is adopted to specifically inhibit expression or activity of PAPSS2, so that the pathway is intervened to block a metabolic reprogramming process of bladder cancer, and the core is to inhibit PAPSS2-mediated p53 sulfurylation modification and recover an inhibition function of p53 on purine metabolism. According to the invention, the feasibility and effectiveness of bladder cancer metabolism targeted therapy are obviously improved.

The invention provides application of a xanthine derivative in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction, and belongs to the technical field of medicine preparation. The invention relates to an application of a xanthine derivative 8-[(2, 3-dihydroxy propyl) sulfo]-3-methyl-7-[(4-methylphenyl) methyl]-1H-purine-2, 6-diketone in preparation of a medicine for preventing and / or treating fatty liver diseases related to metabolic dysfunction. The xanthine derivative has dual efficacy of improving liver cell insulin sensitivity and / or reducing liver cell lipid accumulation, and provides a new way for treatment of metabolic dysfunction related fatty liver diseases and preparation of related clinical drugs.

A Toll-like receptor (TLR) is an indispensable component of an innate immune system and plays a key role in identifying and coping with microbial pathogens. TLR7, TLR8, and TLR9 are located in the endosome-lysosome compartment within the cell and then exclusively used to detect nucleic acids of a microorganism after the microorganism is swallowed and reaches the endosome compartment. The biological importance of the TLR agonists lies in that they can be used as powerful tools for studying innate immune responses, developing vaccines and potential therapeutic applications. In addition, TLR agonists have been explored for use as immunotherapy, while these TLR antagonists can be used as new pathogenic nodes in the context of different autoimmune diseases. Therefore, the agonists and antagonists of the endosomal TLR have therapeutic significance in different clinical backgrounds. The previous study on 8-oxo adenines shows that the C-6-site-NH2 group is extremely important for the recognition of agonistic active sites and the subsequent induction of interferon (IFN). The present invention explores the ability of a hydrogen-substituted 8-oxopurine derivative that does not contain an essential C-6 amine group. The C-6 amino group in the 8-oxopurine derivative is substituted by hydrogen (H), providing an exciting opinion for regulating the endosome TLRs (Toll-Like Receptors). The ability of 8-oxopurine derivatives to modulate the endosomal TLR has been reported, which derivatives are related / interrelated to various substitutions at N-7, N-9 and C-2, all derivatives containing hydrogen at C-6. Structure 1

The invention discloses application of rosmarinic acid in preparation of a medicine or health food for preventing and treating hyperuricemia of a patient with renal insufficiency. The medicine for preventing and treating hyperuricemia of the patient with renal insufficiency is an XOD inhibitor or an ABCG2 gene expression promoter. The rosmarinic acid can significantly reduce the serum uric acid level of HUA mice induced by high purine diet, promote ABCG2-mediated intestinal uric acid excretion, and relieve HUA-induced intestinal inflammation and barrier injury by adjusting intestinal flora. The rosmarinic acid is safe and free of toxic and side effects, and has very important application prospects.

The invention relates to the technical field of functional beer preparation, in particular to a preparation method and application of low-purine beer rich in characteristic flavone components from brassica rapa. Comprising the following steps: preparation of a brassica rapa extract, preparation of low-purine wort and three-stage addition of the brassica rapa extract: adding the extract in the step (1) in different process stages for three times so as to control the accumulative heating time of the extract in a high-temperature stage to be less than or equal to 20 minutes, adding the extract in a saccharification stage for the first time, and adding the extract in an amount which is 30-40% of the total amount of the extract; the second time of addition is 15-20 min before wort boiling, and the addition amount is 45-55% of the total amount of the extract; the third-time addition is performed at the later stage of fermentation, and the addition amount is 10-20% of the total amount of the extract. According to the method, through an innovative three-section type adding process, the accumulative heating time and the fusion stage of characteristic flavone components in the brassica rapa extract in the brewing process are accurately controlled, the activity of the brassica rapa extract is protected to the maximum extent, and the technical problems that the brassica rapa extract is poor in stability and low in retention rate in a beer brewing system are solved.

The invention belongs to the technical field of biological fermentation, and particularly relates to a preparation method and application of a fermented rhizoma smilacis glabrae extract. The invention relates to a fermented rhizoma smilacis glabrae extract, which is characterized in that a lactobacillus rhamnosus LR.M8 strain is utilized, the inhibition effect of the rhizoma smilacis glabrae extract on xanthine oxidase is improved through fermentation, and the treatment effect of the rhizoma smilacis glabrae extract on hyperuricemia is improved. The solution for improving the effect of the extract through biological fermentation is provided for solving the problems that the content of effective components in common medicinal and edible extracts is low, and the human body utilization rate is not high. The lactobacillus rhamnosus LR.M8 can effectively improve the adjusting effect of the rhizoma smilacis glabrae medicine and food homologous plant extract on uric acid balance, can reduce damage of inflammation to cells, and promotes in-vivo purine metabolism to recover balance. The fermentation method provided by the invention is simple and remarkable in effect, and has a wide application prospect.

The present invention belongs to the technical field of medicine; relates to a crystal form of an 8-chloro-3-pentyl-3,7-dihydro-1H-purin-2,6-dione compound and a preparation method therefor; and particularly relates to a crystal form of a compound as represented by formula (1), a method for preparing the crystal form of the compound as represented by formula (1), a composition and a preparation containing the crystal form, and the use of the crystal form thereof or the composition and the preparation containing the crystal form in the preparation of a drug for reducing uric acid and resisting inflammation and / or treating and / or preventing uric acid diseases and / or gouty diseases.